Malignant tumours of temporomandibular joint

BMC Cancer

Yuan Luo¹  Meng-meng Lu¹  Meng Wang¹  Hui Liu¹  Lei Feng¹  Alimujiang Wushou¹  Zhi-cheng Yang¹  Chen-xi Yu²  Feiluore Yibulayin³ 

[1] Department of Oral & Maxillofacial Surgery and Oral Biomedical Engineering Laboratory Shanghai Stomatological Hospital Fudan University, 356 Beijing East Road, 200001, Shanghai, People’s Republic of China;Department of Oral & Maxillofacial Surgery and Oral Biomedical Engineering Laboratory Shanghai Stomatological Hospital Fudan University, 356 Beijing East Road, 200001, Shanghai, People’s Republic of China;Department of Clinical Medicine, Shanghai Medical College, Fudan University, 200001, Shanghai, People’s Republic of China;Department of Oral & Maxillofacial Surgery and Oral Biomedical Engineering Laboratory Shanghai Stomatological Hospital Fudan University, 356 Beijing East Road, 200001, Shanghai, People’s Republic of China;Department of Preventive Medicine, School of Public Health, Shanghai Medical College, Fudan University, 200001, Shanghai, People’s Republic of China;

关键词: Temporomandibular joint;    Malignant tumour;    SEER analysis;   

DOI  :  10.1186/s12885-020-07425-9

来源: Springer

【 摘 要 】

BackgroundMalignant tumours of the temporomandibular joint (MTTMJ) are extremely rare. Studies describing its unique epidemiology, clinicopathological features, treatment and prognosis comprehensively are limited. To address these issues, current investigation was performed.MethodsA retrospective research was carried out by using population-based data from the Surveillance, Epidemiology, and End Results database (1973–2016).ResultsData for a total of 734 patients, including 376 men and 358 women, was found. The median age was 47 years. The 5-year and 10-year disease specific survival (DSS) rates were 69.2 and 63.6%, respectively. Significant differences in DSS were found according to age, race, tumour type, AJCC/TNM stage, surgery, radiotherapy, chemotherapy and different treatment modalities (P < 0.05). In the multivariate survival analysis, age > 44 years and AJCC stage III and IV were associated with poor DSS.ConclusionMTTMJ was mostly found in white people with a median age of 47 years without any sex predominance. Patient’s age and AJCC stage was independent predictor of DSS.

【 授权许可】

CC BY